Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19-4-1BB CAR-T cells (Xuzhou Medical University)
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-CD19-4-1BB CAR-T cells (Xuzhou Medical University) is an investigational second-generation chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of B-cell malignancies, including B-cell leukemia and B-cell lymphoma. The therapy involves genetically engineering a patient's T-cells to express a CAR that specifically targets the B-lymphocyte antigen CD19, which is widely expressed on the surface of B-lineage cells. The CAR construct incorporates a CD19-binding domain linked to a 4-1BB (CD137) costimulatory domain and a CD3 zeta (CD3ζ) signaling domain. This design is intended to promote robust T-cell activation, expansion, and long-term persistence following infusion. In clinical research conducted by Xuzhou Medical University, this therapy is frequently evaluated in combination with other CAR-T products, such as anti-CD22 CAR-T cells, to mitigate the risk of tumor relapse caused by antigen escape.
- Other names
- CD19-4-1BB CAR-TCD-19-4-1BB CAR-TCD 19-4-1BB CAR-TαCD19-TCRz-41BB CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)CD247 (T-cell surface glycoprotein CD3 epsilon chain)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on anti-CD19-4-1BB CAR-T cells (Xuzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19-4-1BB CAR-T cells (Xuzhou Medical University).